ID

43860

Descripción

Dose-finding Study of LIK066 Compared With Placebo or Sitagliptin to Evaluate Change in HbA1c in Patients With Diabetes; ODM derived from: https://clinicaltrials.gov/show/NCT01824264

Link

https://clinicaltrials.gov/show/NCT01824264

Palabras clave

Versiones (2)
  1. 25/6/16 25/6/16 -
  2. 20/9/21 20/9/21 -
Subido en

20 de septiembre de 2021

DOI

Para solicitar uno, por favor iniciar sesión.

Licencia

Creative Commons BY 4.0
Comentarios del modelo :

Puede comentar sobre el modelo de datos aquí. A través de las burbujas de diálogo en los grupos de elementos y elementos, puede agregar comentarios específicos.

Volver a los comentarios del modelo
Comentarios de grupo de elementos para :

Comentarios del elemento para :

Para descargar modelos de datos, debe haber iniciado sesión. Por favor iniciar sesión o Registrate gratis.

Eligibility Type 2 Diabetes Mellitus NCT01824264

Inglés

Eligibility Type 2 Diabetes Mellitus NCT01824264

1 formularios  
Inclusion Criteria
Descripción

Inclusion Criteria

Alias
UMLS CUI
C1512693
1. confirmed diagnosis of t2dm by standard criteria
Descripción

Diabetes Mellitus, Non-Insulin-Dependent

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0011860
2. drug-naïve patients, defined as patients not having received any anti-diabetic medication previously,
Descripción

Therapy naive | Antidiabetics

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0919936
UMLS CUI [2]
C0935929
3. currently untreated patients , who, after the diagnosis of t2dm, have received anti-diabetic medication for not more than 12 consecutive weeks, and have not received any anti-diabetic treatment within 12 weeks prior to visit 1
Descripción

Diabetes Mellitus, Non-Insulin-Dependent Antidiabetics | Diabetes Therapy

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0011860
UMLS CUI [1,2]
C0935929
UMLS CUI [2]
C3274787
4. patients being treated with mono-therapy for at least 8 consecutive weeks prior to visit 1 with the following oads: metformin, dipeptidyl peptidase-4 inhibitors (dpp-4i), su, glinide, alpha-glucosidase inhibitor (agi)
Descripción

Therapeutic procedure Antidiabetics Oral | Metformin | Dipeptidyl Peptidase 4 Inhibitors | Sulfonylurea | Glinide | alpha-Glucosidase Inhibitors

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0087111
UMLS CUI [1,2]
C0935929
UMLS CUI [1,3]
C1527415
UMLS CUI [2]
C0025598
UMLS CUI [3]
C2917254
UMLS CUI [4]
C0038766
UMLS CUI [5]
C2266929
UMLS CUI [6]
C1299007
5. hba1c ≥ 7 to ≤ 10.5% at visit 1 for drug-naïve/currently untreated patients
Descripción

Glycosylated hemoglobin A Therapy naive

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0019018
UMLS CUI [1,2]
C0919936
6. hba1c ≥ 7 to ≤ 9.5% at visit 1 for patients treated with oad monotherapy
Descripción

Glycosylated hemoglobin A Therapeutic procedure Antidiabetics Oral

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0019018
UMLS CUI [1,2]
C0087111
UMLS CUI [1,3]
C0935929
UMLS CUI [1,4]
C1527415
7. hba1c ≥ 7 to ≤ 10.5% at visit 199 for all patients
Descripción

Glycosylated hemoglobin A Patients All

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0019018
UMLS CUI [1,2]
C0030705
UMLS CUI [1,3]
C0444868
8. age: ≥18 and ≤ 75 years old at visit 1
Descripción

Age

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0001779
9. bmi ≥22 to ≤45 kg/m2 at visit 1
Descripción

Body mass index

Tipo de datos

boolean

Alias
UMLS CUI [1]
C1305855
Exclusion Criteria
Descripción

Exclusion Criteria

Alias
UMLS CUI
C0680251
1. fpg ≥270 mg/dl (15 mmol/l) for drug-naïve/currently untreated patients or ≥240 mg/dl (13.3 mmol/l) for patients on oad monotherapy at visit 1
Descripción

Plasma fasting glucose measurement Therapy naive | Plasma fasting glucose measurement Therapeutic procedure Antidiabetics Oral

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0583513
UMLS CUI [1,2]
C0919936
UMLS CUI [2,1]
C0583513
UMLS CUI [2,2]
C0087111
UMLS CUI [2,3]
C0935929
UMLS CUI [2,4]
C1527415
2. insulin treatment >4 consecutive weeks in the last 6 months, corticosteroid use >7 days in the last 8 weeks, use of growth hormones in the last 6 months, or use of weight control products > 4 weeks in the last 6 months
Descripción

Insulin regime | corticosteroid use | Growth Hormone Use | weight control agent Use

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0557978
UMLS CUI [2]
C0239126
UMLS CUI [3,1]
C0037663
UMLS CUI [3,2]
C1524063
UMLS CUI [4,1]
C0597686
UMLS CUI [4,2]
C1524063
3. history of acute metabolic complications, cv disease, type 1 diabetes mellitus, hepatic disorders, pancreatitis, chronic diarrhea
Descripción

Acute metabolic disorder | Cardiovascular Diseases | Diabetes Mellitus, Insulin-Dependent | Liver diseases | Pancreatitis | Chronic diarrhea

Tipo de datos

boolean

Alias
UMLS CUI [1]
C1290840
UMLS CUI [2]
C0007222
UMLS CUI [3]
C0011854
UMLS CUI [4]
C0023895
UMLS CUI [5]
C0030305
UMLS CUI [6]
C0401151
4. significant lab abnormalities such as tsh outside of normal range, uacr>300 mg/g creatinine, egfr <60 ml/min/1.73m2, hemoglobin <12 g/l in men and <11 g/l in women, hematuria
Descripción

Laboratory test result abnormal Significant | Thyroid stimulating hormone measurement Abnormal | Urine albumin/creatinine ratio measurement Creatinine measurement | Estimated Glomerular Filtration Rate | Hemoglobin measurement Gender | Hematuria

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0438215
UMLS CUI [1,2]
C0750502
UMLS CUI [2,1]
C0202230
UMLS CUI [2,2]
C0205161
UMLS CUI [3,1]
C0455271
UMLS CUI [3,2]
C0201975
UMLS CUI [4]
C3811844
UMLS CUI [5,1]
C0518015
UMLS CUI [5,2]
C0079399
UMLS CUI [6]
C0018965
5. ecg abnormalities including av block, long qt syndrome or qtc>450 msec for men and >470 msec for women
Descripción

ECG abnormality | Atrioventricular Block | Long QT Syndrome | QTc Gender

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0522055
UMLS CUI [2]
C0004245
UMLS CUI [3]
C0023976
UMLS CUI [4,1]
C0860814
UMLS CUI [4,2]
C0079399
6. history of malignancy
Descripción

Malignant Neoplasms

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0006826
7. women of child-bearing potential not using effective methods of contraception other protocol-defined inclusion/exclusion criteria may apply
Descripción

Childbearing Potential Contraceptive methods Not used

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C3831118
UMLS CUI [1,2]
C0700589
UMLS CUI [1,3]
C0445107
Volver a la parte superior de la página

Similar models

Eligibility Type 2 Diabetes Mellitus NCT01824264

1 formularios
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de datos
Alias
Item Group
C1512693 (UMLS CUI)
Diabetes Mellitus, Non-Insulin-Dependent
Item
1. confirmed diagnosis of t2dm by standard criteria
boolean
C0011860 (UMLS CUI [1])
Therapy naive | Antidiabetics
Item
2. drug-naïve patients, defined as patients not having received any anti-diabetic medication previously,
boolean
C0919936 (UMLS CUI [1])
C0935929 (UMLS CUI [2])
Diabetes Mellitus, Non-Insulin-Dependent Antidiabetics | Diabetes Therapy
Item
3. currently untreated patients , who, after the diagnosis of t2dm, have received anti-diabetic medication for not more than 12 consecutive weeks, and have not received any anti-diabetic treatment within 12 weeks prior to visit 1
boolean
C0011860 (UMLS CUI [1,1])
C0935929 (UMLS CUI [1,2])
C3274787 (UMLS CUI [2])
Therapeutic procedure Antidiabetics Oral | Metformin | Dipeptidyl Peptidase 4 Inhibitors | Sulfonylurea | Glinide | alpha-Glucosidase Inhibitors
Item
4. patients being treated with mono-therapy for at least 8 consecutive weeks prior to visit 1 with the following oads: metformin, dipeptidyl peptidase-4 inhibitors (dpp-4i), su, glinide, alpha-glucosidase inhibitor (agi)
boolean
C0087111 (UMLS CUI [1,1])
C0935929 (UMLS CUI [1,2])
C1527415 (UMLS CUI [1,3])
C0025598 (UMLS CUI [2])
C2917254 (UMLS CUI [3])
C0038766 (UMLS CUI [4])
C2266929 (UMLS CUI [5])
C1299007 (UMLS CUI [6])
Glycosylated hemoglobin A Therapy naive
Item
5. hba1c ≥ 7 to ≤ 10.5% at visit 1 for drug-naïve/currently untreated patients
boolean
C0019018 (UMLS CUI [1,1])
C0919936 (UMLS CUI [1,2])
Glycosylated hemoglobin A Therapeutic procedure Antidiabetics Oral
Item
6. hba1c ≥ 7 to ≤ 9.5% at visit 1 for patients treated with oad monotherapy
boolean
C0019018 (UMLS CUI [1,1])
C0087111 (UMLS CUI [1,2])
C0935929 (UMLS CUI [1,3])
C1527415 (UMLS CUI [1,4])
Glycosylated hemoglobin A Patients All
Item
7. hba1c ≥ 7 to ≤ 10.5% at visit 199 for all patients
boolean
C0019018 (UMLS CUI [1,1])
C0030705 (UMLS CUI [1,2])
C0444868 (UMLS CUI [1,3])
Age
Item
8. age: ≥18 and ≤ 75 years old at visit 1
boolean
C0001779 (UMLS CUI [1])
Body mass index
Item
9. bmi ≥22 to ≤45 kg/m2 at visit 1
boolean
C1305855 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
Plasma fasting glucose measurement Therapy naive | Plasma fasting glucose measurement Therapeutic procedure Antidiabetics Oral
Item
1. fpg ≥270 mg/dl (15 mmol/l) for drug-naïve/currently untreated patients or ≥240 mg/dl (13.3 mmol/l) for patients on oad monotherapy at visit 1
boolean
C0583513 (UMLS CUI [1,1])
C0919936 (UMLS CUI [1,2])
C0583513 (UMLS CUI [2,1])
C0087111 (UMLS CUI [2,2])
C0935929 (UMLS CUI [2,3])
C1527415 (UMLS CUI [2,4])
Insulin regime | corticosteroid use | Growth Hormone Use | weight control agent Use
Item
2. insulin treatment >4 consecutive weeks in the last 6 months, corticosteroid use >7 days in the last 8 weeks, use of growth hormones in the last 6 months, or use of weight control products > 4 weeks in the last 6 months
boolean
C0557978 (UMLS CUI [1])
C0239126 (UMLS CUI [2])
C0037663 (UMLS CUI [3,1])
C1524063 (UMLS CUI [3,2])
C0597686 (UMLS CUI [4,1])
C1524063 (UMLS CUI [4,2])
Acute metabolic disorder | Cardiovascular Diseases | Diabetes Mellitus, Insulin-Dependent | Liver diseases | Pancreatitis | Chronic diarrhea
Item
3. history of acute metabolic complications, cv disease, type 1 diabetes mellitus, hepatic disorders, pancreatitis, chronic diarrhea
boolean
C1290840 (UMLS CUI [1])
C0007222 (UMLS CUI [2])
C0011854 (UMLS CUI [3])
C0023895 (UMLS CUI [4])
C0030305 (UMLS CUI [5])
C0401151 (UMLS CUI [6])
Laboratory test result abnormal Significant | Thyroid stimulating hormone measurement Abnormal | Urine albumin/creatinine ratio measurement Creatinine measurement | Estimated Glomerular Filtration Rate | Hemoglobin measurement Gender | Hematuria
Item
4. significant lab abnormalities such as tsh outside of normal range, uacr>300 mg/g creatinine, egfr <60 ml/min/1.73m2, hemoglobin <12 g/l in men and <11 g/l in women, hematuria
boolean
C0438215 (UMLS CUI [1,1])
C0750502 (UMLS CUI [1,2])
C0202230 (UMLS CUI [2,1])
C0205161 (UMLS CUI [2,2])
C0455271 (UMLS CUI [3,1])
C0201975 (UMLS CUI [3,2])
C3811844 (UMLS CUI [4])
C0518015 (UMLS CUI [5,1])
C0079399 (UMLS CUI [5,2])
C0018965 (UMLS CUI [6])
ECG abnormality | Atrioventricular Block | Long QT Syndrome | QTc Gender
Item
5. ecg abnormalities including av block, long qt syndrome or qtc>450 msec for men and >470 msec for women
boolean
C0522055 (UMLS CUI [1])
C0004245 (UMLS CUI [2])
C0023976 (UMLS CUI [3])
C0860814 (UMLS CUI [4,1])
C0079399 (UMLS CUI [4,2])
Malignant Neoplasms
Item
6. history of malignancy
boolean
C0006826 (UMLS CUI [1])
Childbearing Potential Contraceptive methods Not used
Item
7. women of child-bearing potential not using effective methods of contraception other protocol-defined inclusion/exclusion criteria may apply
boolean
C3831118 (UMLS CUI [1,1])
C0700589 (UMLS CUI [1,2])
C0445107 (UMLS CUI [1,3])
Volver a la parte superior de la página 

Contacto

Utilice este formulario para comentarios, preguntas y sugerencias.

Los campos marcados con * son obligatorios.

Ayuda

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial